Please use this identifier to cite or link to this item: http://docs.prosentient.com.au/prosentientjspui/handle/1/10879
Title: Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever.
Authors: Wyber, Rosemary
Boyd, Ben J
Colquhoun, Samantha
Currie, Bart J
Engel, Mark
Kado, Joseph
Karthikeyan, Ganesan
Sullivan, Mark
Saxena, Anita
Sheel, Meru
Steer, Andrew
Mucumbitsi, Joseph
Zühlke, Liesl
Carapetis, Jonathan
Affiliation: Telethon Kids Institute, University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia. Rosemary.Wyber@telethonkids.org.au..
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, Australia..
Murdoch Childrens Research Institute, University of Melbourne, Parkville, Australia..
Menzies School of Health Research, Charles Darwin University, Darwin, Australia.. Royal Darwin Hospital, Darwin, Australia..
Department of Medicine, University of Cape Town, Cape Town, South Africa..
College of Medicine, Nursing and Health Sciences, Fiji National University, Suva, Fiji..
Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India..
Medicines Development for Global Health, Melbourne, Australia..
Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India..
Telethon Kids Institute, University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia..
Group A Streptococcal Research Group, Murdoch Children's Research, University of Melbourne, Melbourne, Australia..
Department of Paediatrics, King Faisal Hospital, Kigali, Rwanda..
Department of Paediatric Cardiology, University of Cape Town, Cape Town, South Africa..
Telethon Kids Institute, University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia.. Princess Margaret Hospital for Children, Perth, Western Australia, Australia..
Issue Date: 2016
Citation: Drug delivery and translational research 2016; 6(5): 572-8
Abstract: Rheumatic fever is caused by an abnormal immune reaction to group A streptococcal infection. Secondary prophylaxis with antibiotics is recommended for people after their initial episode of rheumatic fever to prevent recurrent group A streptococcal infections, recurrences of rheumatic fever and progression to rheumatic heart disease. This secondary prophylaxis must be maintained for at least a decade after the last episode of rheumatic fever. Benzathine penicillin G is the first line antibiotic for secondary prophylaxis, delivered intramuscularly every 2 to 4 weeks. However, adherence to recommended secondary prophylaxis regimens is a global challenge. This paper outlines a consultation with global experts in rheumatic heart disease on the characteristics of benzathine penicillin G formulations which could be changed to improve adherence with secondary prophylaxis. Characteristics included dose interval, pain, administration mechanism, cold chain independence and cost. A sample target product profile for reformulated benzathine penicillin G is presented.
URI: http://docs.prosentient.com.au/prosentientjspui/handle/1/10879
DOI: 10.1007/s13346-016-0313-z
Type: Journal Article
Research Support, Non-U.S. Gov't
Subjects: Benzathine
Fever
Heart
Penicillin
Prophylaxis
Rheumatic
Drug Compounding
Humans
Penicillin G Benzathine
Rheumatic Fever
Secondary Prevention
Attitude of Health Personnel
Drug Delivery Systems
Appears in Collections:NT Health digital library

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.